AARD vs TENX
AARD: Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing its lead small molecule candidate, ARD-101, for metabolic and rare disease indications. TENX: A Phase 3 development-stage pharmaceutical company developing novel cardiopulmonary therapies, primarily levosimendan for pulmonary hypertension and imatinib for pulmonary arterial hypertension.
Side-by-side fundamentals
| Metric | AARD | TENX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.48 | $14.79 | |
| Market cap as of 2026-07-23 | $128M | $418M | |
| PEG as of 2026-07-23 | -1.17 | n/a | |
| Net margin as of 2026-07-23 | n/a | -10115.8% | |
| Gross margin as of 2026-07-23 | n/a | +100.0% | |
| Operating margin as of 2026-07-23 | n/a | -10390.5% | |
| ROE as of 2026-07-23 | -61.7% | -56.3% | TENX higher |
| ROA as of 2026-07-23 | -56.3% | -53.1% | TENX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -82.9% | |
| Beta as of 2026-07-23 | 4.01 | 0.95 | |
| 1-year return as of 2026-07-22 close | -49.3% | +145.7% | TENX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.